Monoclonal anti‐idiotypic antibody mimicking a tumor‐associated sialoglycoprotein antigen induces humoral immune response against human small‐cell lung carcinoma

Barth, Andreas S.; Waibel, Robert; Stahel, Rolf A.

doi:10.1002/ijc.2910430527

Cited by 18 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies have documented that Ab2 could be [73,74]. In this regard, monoclonal Ab2s elicited with a MoAb against a cluster 5 and 5a antigen (TA sialoglycoprotein) have recently been reported [75,76]. Their injection in mouse and rat species produces an Ab3 response effective against SCLC cell lines sharing the cluster 5a antigen.…”

Section: Mediators Of Immune Effector Functionmentioning

confidence: 99%

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Weynants

Marchandise²,

Sibille³

1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

Section: Mediators Of Immune Effector Functionmentioning

confidence: 99%

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Weynants

Marchandise²,

Sibille³

1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…The 3 anti-idiotypic hybridomas LY8-229, LX8-531 and LX8-632 were each selected for the ability of their secreted Ab2 to inhibit, by more than 95%, LAM8 binding to sialoglycoprotein sGP,,,~,,,, as described earlier (Barth et al, 1988(Barth et al, , 1989. All affinity-purified Ab2 showed similar inhibition of LAM8 binding to SW2 cells (Fig.…”

Section: Characterization Ofab2mentioning

confidence: 94%

“…These findings suggested clinical relevance of LY8-229 as a "tumor marker" for SCLC in serological assays, as described for a breast-carcinoma antigenic system (Viale et al., 1987). The potential of this Ab2 to be used as a surrogate tumor vaccine for SCLC patients was pointed out in an earlier study (Barth et al, 1989). …”

mentioning

confidence: 97%

See 1 more Smart Citation

Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma

Lehmann

Zwicky

Waibel

et al. 1992

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

We have previously developed 3 monoclonal anti-idiotypic antibodies (Ab2) of LOU rat origin directed against the binding site of the murine monoclonal IgM LAM8, which recognizes the small-cell lung carcinoma (SCLC)-associated sialoglycoprotein antigen sGP 90-135. The aim of this study was to compare the efficiencies of these 3 Ab2, designated LY8-229, LX8-531 and LX8-632, to induce antigen-specific immunity in different animal species without prior exposure of the recipients to the nominal antigen, and thereby possibly select an Ab2 candidate for active immunotherapy against SCLC in patients. The feasibility of this approach was further evaluated by a serological analysis of patients with SCLC compared with healthy individuals, in whom the spontaneous antibody reactivities against SCLC cell lines and Ab2 were tested. LY8-229 was shown to be the most effective Ab2 in inducing antigen-specific antibodies in BALB/c mice, CBA/J/Zur mice and one NZW rabbit. Furthermore, LY8-229 was the only Ab2 against which significantly elevated idiotype-specific antibody reactivities existed in sera of patients with SCLC. These reactivities correlated positively with binding to antigen-positive tumor cells. Our findings suggest that LY8-229 represents in its reactivity pattern the nominal SCLC antigen in humans also, and therefore may be of diagnostic and possibly therapeutic relevance for patients with SCLC.

show abstract

“…The selective expression of these antigens suggest their use as targets for specific immunotherapy, including immunisation with anti-idiotypic antibodies. Previously, we have reported on the generation of monoclonal anti-idiotypic antibodies to cluster-5 antigen (Barth et al, 1989). We now report on the generation of polyclonal goat anti-idiotypic antibodies (ab2) against antibody SWA20 (abl), describe the reactivity of these ab2 with a series of monoclonal antibodies to different SCLC antigens and summarise results on the induction of the humoral anti-anti-idiotypic (ab3) immune response by immunising animals with ab2.…”

mentioning

confidence: 99%

Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals

Zwicky

Stahel²,

Jaksche³

et al. 1991

Lung Cancer

View full text Add to dashboard Cite

Summary Polyclonal anti-idiotypic antibodies (ab2) were generated by immunising goats with the murine IgG2a monoclonal antibody SWA20 which recognises the SCLC antigen cluster-SA, a tumour-associated sialoglycoprotein. Ab2 was shown to bind specifically to antibody SWA20, but not to isotype matched control antibodies. Pre-incubation with ab2 completely inhibited target cell binding of antibody SWA20 and of four other antibodies to cluster-5A antigen, while no effect was seen with antibodies to cluster-I and cluster-w4 antigen. By these criteria the ab2 population consists of antibodies resembling in their reactivity pattern the cluster-5A antigen. Ab2 was used for immunisation of rabbits and two strains of mice; control animals received PBS or nonspecific goat IgG. Anti-anti-idiotype sera (ab3) were analysed in a series of radioimmunoassays for reactivity with goat IgG and reactivity with ab2. After blocking the nonspecific anti-goat response, ab3 could be shown to bind specifically to ab2 idiotype. As (Forstrom et al., 1983;Kennedy et al., 1985), mouse mammary carcinoma (Gorczynski et al., 1984), rat sarcoma (Dunn et al., 1986), and mouse lymphoma . Anti-idiotypic antibodies to murine monoclonal antibodies recognising surface antigens of human tumours have been developed in several antigenic systems, including the melanoma antigen p97 (Nepom et al., 1985), gastric carcinoma antigen GA733 (Herlyn et al., 1985), colon carcinoma antigen 17-lA (Herlyn et al., 1987), and a high molecular weight melanoma antigen (Kusama et al., 1989). In the latter two systems, results of the clinical use of anti-idiotypic antibodies have been published. The studies have demonstrated that anti-idiotypic antibodies can be safely administered and that an anti-anti-idiotypic (ab3) response can be obtained in the majority of patients (Herlyn et al., 1987;O'Connell et al., 1989). Occasional clinical responses occurred, but due to the design of the studies cannot yet be attributed with certainty to an immune response against the tumour-associated antigens elicited by the administration of anti-idiotypic antibodies.We have previously identified two tumour-associated sialoglycoprotein antigens given the workshop designation cluster-5 and cluster-SA which are strongly expressed on a proportion of small cell lung carcinomas (SCLC) and are virtually absent from normal adult tissues (Stahel et al., 1987;Waibel et al., 1988

show abstract

Monoclonal anti‐idiotypic antibody mimicking a tumor‐associated sialoglycoprotein antigen induces humoral immune response against human small‐cell lung carcinoma

Cited by 18 publications

References 24 publications

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Pulmonary perspective: immunology in diagnosis and treatment of lung cancer

Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma

Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals

Contact Info

Product

Resources

About